* Lipocine Inc LPCN.OQ LPCN.O is expected to show a rise
in
quarterly revenue when it reports results
* The Salt Lake City Utah-based company is expected to
report
revenue of $307 thousand, according to the mean estimate from 2
analysts, based on LSEG data.
* Refinitiv's mean analyst estimate for Lipocine Inc is for
a
loss of 60 cents per share.
* The one available analyst rating on the shares is "strong
buy".
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Lipocine
Inc is
$38, above its last closing price of $2.58.
This summary was machine generated November 3 at 18:42 GMT. All
figures in US dollars unless otherwise stated